Wockhardt Ltd Right Issue Date, Price, Ratio & Allotment Status
Published 7 Mar 2022 · Main-IPO
Wockhardt: is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 8600 Wockhardt Associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
Wockhardt Rights Issue Date, Details, Price
| Issue Start Date: | 15 March 2022 |
| Issue Close Date: | 22 March 2022 |
| Issue Size | 747.90 Crores |
| Price | 225 Per share |
| Ratio | Issue of 03 equity shares of 10 equity shares held. |
| Face value | 5 per share |
| Market lot | 1 per share |
| Listing At | BSE, NSE |
| Equity | 3.32 Crore |
| Letter | Download |
Wockhardt Rights Issue Timetable
| Record Date: | 09 March 2022 |
| Deemed Date of Allotment: | 30 March 2022 |
| Renunciation of Rights Entitlements: | 16 March 2022 |
Wockhardt Rights Issue Contact Details
Wockhardt Ltd
Wockhardt Towers, Bandra-Kurla Complex
Bandra East, Mumbai 400 051
Phone: +91 22 2659 6228
Email: [email protected]
Website: http://www.wockhardt.com/
Wockhardt Rights Issue Registrar
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai - 400083
Website: https://linkintime.co.in/
Email: [email protected]
Phone: +91-22-4918 6270
Fax: +91-22-4918 6060
Wockhardt Rights Issue Lead Managers
Ambit Private Limited
Original address: https://ipowala.in/wockhardt-ltd-right-issue-date-price-ratio-allotment-status/ · WordPress record 7702
Leave a reply
Your email address will not be published. Required fields are marked *
Comments are readers’ own views. They are checked before they appear, and they are not investment advice or a source of IPO data. For figures and dates, use the issue page and its sources.